Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Anti-DNA Antibody

Microbiology & Infection

Anti-double-stranded DNA antibodyAnti-dsDNAAnti-native DNA antibody

Review status

Currently under review

Pending specialist review and validation.

What it shows

The anti-DNA antibody test looks for autoantibodies in your blood that target your own DNA, most often the double stranded form. These antibodies are closely linked to systemic lupus erythematosus and can appear in some other autoimmune conditions.

A blood sample is analyzed with immunoassays or immunofluorescence methods. Because different methods detect slightly different features of the antibody, results are most useful when compared over time using the same laboratory and technique.

Why it matters

Your clinician may order this test when lupus is suspected based on your symptoms and exam, or to monitor known lupus. A positive result supports the diagnosis when combined with antinuclear antibody testing, other specific autoantibodies, and clinical findings.

Changes in anti-dsDNA levels can parallel disease activity, especially kidney involvement, so this test can help track flares and guide treatment decisions. A negative result lowers the chance of classic lupus but does not exclude it. Some other conditions and certain medicines can produce positive results, so your result is interpreted alongside your history, exam, and other laboratory tests.

Understanding your results

If your result is reported as detected or elevated, it suggests your immune system is reacting to native DNA and may indicate active autoimmune disease. Your clinician will consider your symptoms, exam, and other tests to decide what the finding means for you.

Rising values can accompany a flare, while stable or falling values can align with improvement, but these patterns are not perfect. Your clinician may pair this test with antinuclear antibodies, complement levels, urine studies, and kidney assessment. Using the same laboratory for follow up helps ensure that trends are meaningful.

Reference ranges

099 IU/mL
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Anti-DNA Antibody

  • Test method differences

    Different assays, such as enzyme immunoassay or Crithidia immunofluorescence, can yield different results. Tracking trends is most reliable when the same lab and method are used for repeat testing.

  • Medications and biologics

    Some drugs, including tumor necrosis factor inhibitors and interferons, can trigger autoantibodies and occasional positive anti-dsDNA results. Always tell your clinician about all prescriptions and supplements.

  • Intercurrent infection or stress

    Recent infections or significant physiologic stress may transiently influence autoantibody activity. If results are unexpected, your clinician may recommend retesting after recovery.

  • Pregnancy and postpartum

    Immune changes during pregnancy and after delivery can affect autoimmune activity. If you have lupus, your care team may monitor anti-dsDNA and kidney health more closely during this time.

  • Sample handling and timing

    Improper handling, marked hemolysis, or delayed processing can affect some assays. Proper collection and timely transport help ensure accurate and reproducible results.

  • Other autoimmune or liver disease

    Low level positivity can occasionally be seen in other autoimmune conditions, such as autoimmune hepatitis or Sjogren syndrome. Clinical context is essential for interpretation.

2026

References

  1. McGill University Health Centre. (2009, October 26). Anti-DNA Antibody (Task CD 693037). Laboratory reference ranges.
  2. Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-Goldman, R., Smolen, J. S., Wofsy, D., & Boumpas, D. T. (2019). 2019 European League Against Rheumatism and American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78, 1151–1159. External link
  3. Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2019). Update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases, 78, 736–745. External link
  4. American College of Rheumatology. (2013). Choosing Wisely: Five things physicians and patients should question in rheumatology. External link